Plain-English translation of NCT07704489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a registry study — a long-term database — that collects health information and biological samples (blood, saliva, stool, and sometimes tumor tissue) from patients diagnosed with liver cancer. Researchers will analyze these samples to look for patterns, markers, and genetic clues that might help doctors better understand and treat the disease in the future.
Liver cancer is complex and affects different people in different ways. By gathering information and samples from thousands of patients over time, researchers hope to discover biomarkers — biological signatures — that could help doctors personalize treatment, predict outcomes, and develop new therapies.
You likely qualify if…
You likely don't qualify if…
If you join, you'll continue your regular cancer treatment with no changes to your care plan. You'll simply donate extra biological samples — about 30 mL of blood during routine blood tests, plus saliva and stool samples — at baseline and at several follow-up timepoints over 5 years (at 3, 6, 9, 12 months and when your disease progresses). Researchers may also use tumor tissue that was already collected for your diagnosis. Your medical records and follow-up data will be tracked throughout the study.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Italy
Sponsor
IRCCS San Raffaele
Enrollment target
~4,000 participants
Started
October 2021
Primary completion
October 2050
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Andrea Casadei Gardini, Medical Oncologist
IRCCS San Raffaele
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.